StonvexLoading…
StonvexStonvexStonvexCore line items from VRSK's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-28 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $820.21M | $782.60M | $3.07B | $2.29B | $1.53B |
Operating Income | Not available | $352.20M | $1.34B | $1.03B | $684.40M |
Net Income | Not available | $234.20M | $908.30M | $711.10M | $485.60M |
EPS (Diluted) | $1.97 | $1.73 | $6.48 | $5.06 | $3.45 |
Total Assets | Not available | $4.60B | $6.20B | $6.24B | $4.79B |
Total Liabilities | Not available | $5.77B | $5.89B | $5.86B | $4.48B |
Cash & Equivalents | Not available | $524.50M | $2.18B | $2.11B | $628.70M |
Free Cash Flow OCF − CapEx | Not available | $326.40M | $1.19B | $915.80M | $579.70M |
Shares Outstanding | Not available | 131.02M | 138.40M | 139.37M | 139.70M |